Radiopharm Theranostics (RDPTF) Retained Earnings (2024 - 2026)

Radiopharm Theranostics (RDPTF) has reported Retained Earnings for 3 consecutive years, with -$1.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings fell 51.75% year-over-year to -$1.4 million in Q2 2026; TTM through Jun 2026 was -$1.4 million, a 51.75% decrease from a year earlier, with the FY2026 full-year figure at -$1.4 million, up 99.07% from the prior year.
• Retained Earnings was -$1.4 million for Q2 2026 at Radiopharm Theranostics, down from -$933322.2 in the prior quarter.
• Over five years, Retained Earnings peaked at -$733749.8 in Q2 2024 and troughed at -$127.8 million in Q4 2024.
• A 3-year average of -$32.7 million and a median of -$1.2 million in 2025 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings declined 27.2% in 2025 and tumbled 51.75% in 2026, its largest moves.
• Over 3 years, Retained Earnings stood at -$127.8 million in 2024, then jumped by 99.27% to -$933322.2 in 2025, then plunged by 51.75% to -$1.4 million in 2026.
• The last three Retained Earnings figures came in at -$1.4 million (Q2 2026), -$933322.2 (Q2 2025), and -$127.8 million (Q4 2024), per Business Quant data.